Русский
Investigation of the role of polymorphic loci RS2299941, RS1903858, RS10490920, RS2735343 of the PTEN gene in patients with prostate cancer
DOI: https://dx.doi.org/10.18565/urology.2022.5.59-63
V.N. Pavlov, M.V. Loginova, E.A. Ivanova, A.T. Mustafin, I.R. Gilyazovа
1) FGBOU VO Bashkir State Medical University of the Ministry of Health of the Russian Federation, Ufa, Russia; 2) FGBUN Institute of biochemistry and genetics of Ufa Federal Research center of RAS, Ufa, Russia
Prostate cancer is a clinically heterogeneous disease, and accurate risk stratification of patients is becoming a key clinical task. This is the most common malignant neoplasm and the leading cause of cancer death in men worldwide. Genomic markers include tools and technologies that can predict the probability of an initial positive biopsy, reduce the number of unnecessary repeated biopsies, identify tumors with low, medium and high risk, classify the degree of disease, as well as predict and monitor the clinical response to intervention. Variants of the PTEN gene are of great interest as genetic markers of the risk of developing prostate malignancies.
About the Autors
Corresponding author: M.V. Loginova – oncologist at the Department of Oncology of Antitumor drug therapy №2, Bashkir State Medical University of the Ministry of Health of the Russian Federation, Clinic of Bashkir State Medical University, Ufa, Russia, Ph.D. student at the Department of Urology with a course of postgraduate education of Bashkir State Medical University, Ufa, Russia, e-mail: mariialoginova25@ gmail.com
Similar Articles
